Yahoo

This Common Prenatal Test Can Reveal Hidden Maternal Cancer

A DNA screening to look for fetal abnormalities can render some unexpected results. According to a new analysis, a cell-free DNA screening to test for chromosomal disorders can also reveal undetected ...
Seeking Alpha

Trifecta Study Demonstrates Prospera™ Kidney dd-cfDNA Test Outperforms DSA in Predicting Antibody Mediated Rejection

AUSTIN, Texas, Oct. 4, 2022 /PRNewswire/ -- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of the latest data from the Trifecta ...
Nature

Genome-wide cfDNA screening: clinical laboratory experience with the first 10,000 cases

Invasive diagnostic prenatal testing can provide the most comprehensive information about the genetic status of a fetus. Noninvasive prenatal screening methods, especially when using cell-free DNA ...
Ars Technica

Prenatal test accidentally picks up cancer in 50% of those with wonky results

In 2013, researchers reported an eye-opening case of a healthy pregnant woman with a puzzling prenatal test result. A routine genetic screen using cell-free DNA—a highly accurate blood test—suggested ...
Nasdaq

iMDx Announces Positive Study Results Showing Equivalence of GraftAssureIQ with NGS dd-cfDNA Test Kits in Kidney Transplant Monitoring

Study shows iMDx test equivalent to NGS kits for dd-cfDNA measurement in kidney transplant patients, supporting future commercialization efforts. Results from a head-to-head comparison show iMDx's ...
Business Insider

New Kidney360 Publication Highlights CareDx’s AlloSure is Differentiated as the dd-cfDNA Test of Choice

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of ...
Nature

Prenatal cell-free DNA screening test failures: a systematic review of failure rates, risks of Down syndrome, and impact of repeat testing

We systematically reviewed the published literature on test failure rates for the sequencing of cell-free DNA (cfDNA) in maternal plasma to identify Down syndrome. The aim of this study was to ...
Seeking Alpha

Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) ...
Business Wire

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, ...
Nasdaq

Natera Launches Prospera™ Kidney with Quantification to Further Improve Test Performance, Demonstrating Commitment to Innovation in Transplantation

Validation study published in the Journal of the American Society of Nephrology (JASN) showed improved sensitivity with quantification vs. dd-cfDNA fraction alone AUSTIN, Texas, Sept. 9, 2021 ...
Forbes

New Prenatal DNA Test For Down Syndrome Dramatically Reduces Errors

The results of a new study offer very good news for expectant parents: a remarkably accurate prenatal genetic test for Down syndrome that requires only a blood sample from the mother. Expectant ...